Strope BS, Pendleton KE, Bowie WZ, Echeverria GV, Zhu Q. (2024). Xenomake: A pipeline for processing and sorting xenograft reads from spatial transcriptomic experiments.   Bioinformatics (Oxford, England), , (), . pii: btae608. doi: 10.1093/bioinformatics/btae608. 39400332

Talwar C, Davuluri GVN, Kamal AHM, Coarfa C, Han SJ, Veeraragavan S, Parsawar K, Putluri N, Hoffman K, Jimenez P, Biest S, Kommagani R. (2024). Identification of distinct stool metabolites in women with endometriosis for non-invasive diagnosis and potential for microbiota-based therapies.   Med (New York, N.Y.), , (), . pii: S2666-6340(24)00373-8. doi: 10.1016/j.medj.2024.09.006. 39395412

Massey S, Kongchan N, Gao Y, Chaudhury A, Olokpa E, Karch J, Malovannaya A, Cheng C, Zhang X, Neilson JR. (2024). PKC-mediated phosphorylation governs the stability and function of CELF1 as a driver of EMT in breast epithelial cells.   The Journal of biological chemistry, , (), 107826. doi: 10.1016/j.jbc.2024.107826. 39343007

Berner MJ, Beasley HK, Vue Z, Lane A, Vang L, Baek ML, Marshall AG, Killion M, Zeleke F, Shao B, Parker D, Peterson A, Rhoades JS, Scudese E, Dobrolecki LE, Lewis MT, Hinton A Jr, Echeverria GV. (2024). Three-dimensional analysis of mitochondria in a patient-derived xenograft model of triple negative breast cancer reveals mitochondrial network remodeling following chemotherapy treatments.   bioRxiv : the preprint server for biology, , (), . pii: 2024.09.09.611245. doi: 10.1101/2024.09.09.611245. 39314272

Nipper AJ, Warren EAK, Liao KS, Liu HC, Michikawa C, Porter CE, Wells GA, Villanueva M, Brasil da Costa FH, Veeramachaneni R, Villanueva H, Suzuki M, Sikora AG. (2024). Chick Embryo Chorioallantoic Membrane as a Platform for Assessing the In Vivo Efficacy of Chimeric Antigen Receptor T-cell Therapy in Solid Tumors.   ImmunoHorizons, 8, (8), 598-605. doi: 10.4049/immunohorizons.2400059. 39225630

Meric-Bernstam F, Lloyd MW, Koc S, Evrard YA, McShane LM, Lewis MT, Evans KW, Li D, Rubinstein L, Welm A, Dean DA 2nd, Srivastava A, Grover JW, Ha MJ, Chen H, Huang X, Varadarajan K, Wang J, Roth JA, Welm B, Govinden R, Ding L, Kaochar S, Mitsiades N, Carvajal-Carmona L, Herylyn M, Davies MA, Shapiro GI, Fields R, Trevino JG, Harrell JC, NCI PDXNet Consortium, Doroshow JH, Chuang JH, Moscow JA. (2024). Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations.   Molecular cancer therapeutics, 23, (7), 924-938. doi: 10.1158/1535-7163.MCT-23-0471. 38641411

Murthy D, Dutta D, Attri KS, Samanta T, Yang S, Jung KH, Latario SG, Putluri V, Huang S, Putluri N, Park JH, Kaipparettu BA. (2024). CD24 negativity reprograms mitochondrial metabolism to PPARα and NF-κB-driven fatty acid β-oxidation in triple-negative breast cancer.   Cancer letters, 587, (), 216724. doi: 10.1016/j.canlet.2024.216724. 38373689

Espinoza AF, Patel RH, Patel KR, Badachhape AA, Whitlock R, Srivastava RK, Govindu SR, Duong A, Kona A, Kureti P, Armbruster B, Kats D, Srinivasan RR, Dobrolecki LE, Yu X, Najaf Panah MJ, Zorman B, Sarabia SF, Urbicain M, Major A, Bissig KD, Keller C, Lewis MT, Heczey A, Sumazin P, López-Terrada DH, Woodfield SE, Vasudevan SA. (2024). A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma.   Journal of hepatology, 80, (4), 610-621. doi: 10.1016/j.jhep.2024.01.003. 38242326

Lewis MT, Caldas C. (2024). The Power and Promise of Patient-Derived Xenografts of Human Breast Cancer.   Cold Spring Harbor perspectives in medicine, 14, (4), . doi: 10.1101/cshperspect.a041329. 38052483

Amara CS, Kami Reddy KR, Yuntao Y, Chan YS, Piyarathna DWB, Dobrolecki LE, Shih DJH, Shi Z, Xu J, Huang S, Ellis MJ, Apolo AB, Ballester LY, Gao J, Hansel DE, Lotan Y, Hodges HC, Lerner SP, Creighton CJ, Sreekumar A, Zheng WJ, Msaouel P, Kavuri SM, Putluri N. (2024). The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer.   Nature communications, 15, (1), 1373. doi: 10.1038/s41467-024-45132-2. 38355560

Qian J, Ma Y, Tahaney WM, Moyer CL, Lanier A, Hill J, Coleman D, Koupaei N, Hilsenbeck SG, Savage MI, Page BDG, Mazumdar A, Brown PH. (2024). The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth.   Breast cancer research : BCR, 26, (1), 23. doi: 10.1186/s13058-024-01778-w. 38317231

Saltzman AB, Chan DW, Holt MV, Wang J, Jaehnig EJ, Anurag M, Singh P, Malovannaya A, Kim BJ, Ellis MJ. (2024). Kinase inhibitor pulldown assay (KiP) for clinical proteomics.   Clinical proteomics, 21, (1), 3. doi: 10.1186/s12014-023-09448-3. 38225548

Liu Q, Zhang J, Guo C, Wang M, Wang C, Yan Y, Sun L, Wang D, Zhang L, Yu H, Hou L, Wu C, Zhu Y, Jiang G, Zhu H, Zhou Y, Fang S, Zhang T, Hu L, Li J, Liu Y, Zhang H, Zhang B, Ding L, Robles AI, Rodriguez H, Gao D, Ji H, Zhou H, Zhang P. (2024). Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies.   Cell, 187, (1), 184-203.e28. doi: 10.1016/j.cell.2023.12.004. 38181741

Lin FT, Liu K, Garan LAW, Folly-Kossi H, Song Y, Lin SJ, Lin WC. (2023). A small-molecule inhibitor of TopBP1 exerts anti-MYC activity and synergy with PARP inhibitors.   Proceedings of the National Academy of Sciences of the United States of America, 120, (44), e2307793120. doi: 10.1073/pnas.2307793120. 37878724

Gou X, Kim BJ, Anurag M, Lei JT, Young MN, Holt MV, Fandino D, Vollert CT, Singh P, Alzubi MA, Malovannaya A, Dobrolecki LE, Lewis MT, Li S, Foulds CE, Ellis MJ. (2023). Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.   Cancer research, 83, (19), 3237-3251. doi: 10.1158/0008-5472.CAN-22-3484. 37071495

Strope BS, Pendleton KE, Bowie WZ, Echeverria GV, Zhu Q. (2023). Xenomake: a pipeline for processing and sorting xenograft reads from spatial transcriptomic experiments.   bioRxiv : the preprint server for biology, , (), . pii: 2023.09.04.556109. doi: 10.1101/2023.09.04.556109. 37732227

Fu X, Pereira R, Liu CC, De Angelis C, Shea MJ, Nanda S, Qin L, Mitchell T, Cataldo ML, Veeraraghavan J, Sethunath V, Giuliano M, Gutierrez C, Győrffy B, Trivedi MV, Cohen O, Wagle N, Nardone A, Jeselsohn R, Rimawi MF, Osborne CK, Schiff R. (2023). High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer.   Cell reports, 42, (8), 112821. doi: 10.1016/j.celrep.2023.112821. 37467106

Murillo OD, Petrosyan V, LaPlante EL, Dobrolecki LE, Lewis MT, Milosavljevic A. (2023). Deconvolution of cancer cell states by the XDec-SM method.   PLoS computational biology, 19, (8), e1011365. doi: 10.1371/journal.pcbi.1011365. 37578979

Chowdhury S, Kennedy JJ, Ivey RG, Murillo OD, Hosseini N, Song X, Petralia F, Calinawan A, Savage SR, Berry AB, Reva B, Ozbek U, Krek A, Ma W, da Veiga Leprevost F, Ji J, Yoo S, Lin C, Voytovich UJ, Huang Y, Lee SH, Bergan L, Lorentzen TD, Mesri M, Rodriguez H, Hoofnagle AN, Herbert ZT, Nesvizhskii AI, Zhang B, Whiteaker JR, Fenyo D, McKerrow W, Wang J, Schürer SC, Stathias V, Chen XS, Barcellos-Hoff MH, Starr TK, Winterhoff BJ, Nelson AC, Mok SC, Kaufmann SH, Drescher C, Cieslik M, Wang P, Birrer MJ, Paulovich AG. (2023). Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.   Cell, 186, (16), 3476-3498.e35. doi: 10.1016/j.cell.2023.07.004. 37541199

Zhou S, Chai D, Wang X, Neeli P, Yu X, Davtyan A, Young K, Li Y. (2023). AI-powered discovery of a novel p53-Y220C reactivator.   Frontiers in oncology, 13, (), 1229696. doi: 10.3389/fonc.2023.1229696. 37593097

Kim BJ, Zheng ZY, Lei JT, Holt MV, Chen A, Peng J, Fandino D, Singh P, Kennedy H, Dou Y, Chica-Parrado MDR, Bikorimana E, Ye D, Wang Y, Hanker AB, Mohamed N, Hilsenbeck SG, Lim B, Asirvatham JR, Sreekumar A, Zhang B, Miles G, Anurag M, Ellis MJ, Chang EC. (2023). Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment.   Cancer research communications, 3, (7), 1366-1377. doi: 10.1158/2767-9764.CRC-23-0044. 37501682

Sharma S, Woods M, Mehta NU, Sauer T, Parikh KS, Schmuck-Henneresse M, Zhang H, Mehta B, Brenner MK, Heslop HE, Rooney CM. (2023). Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy.   Journal for immunotherapy of cancer, 11, (4), . doi: 10.1136/jitc-2022-006267. 37072346

Baek ML, Lee J, Pendleton KE, Berner MJ, Goff EB, Tan L, Martinez SA, Mahmud I, Wang T, Meyer MD, Lim B, Barrish JP, Porter W, Lorenzi PL, Echeverria GV. (2023). Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment.   Oncogene, 42, (14), 1117-1131. doi: 10.1038/s41388-023-02596-8. 36813854

Ngai H, Barragan GA, Tian G, Balzeau JC, Zhang C, Courtney AN, Guo L, Xu X, Wood MS, Drabek JM, Demberg T, Sands CM, Chauvin-Fleurence CN, Di Pierro EJ, Rosen JM, Metelitsa LS. (2023). LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells.   Cancer immunology research, 11, (2), 171-183. doi: 10.1158/2326-6066.CIR-22-0333. 36484736

Wu T, Li X, Yan G, Tan Z, Zhao D, Liu S, Wang H, Xiang Y, Chen W, Lu H, Liao X, Li Y, Lu Z. (2023). LncRNA BCAR4 promotes migration, invasion, and chemo-resistance by inhibiting miR-644a in breast cancer.   Journal of experimental & clinical cancer research : CR, 42, (1), 14. doi: 10.1186/s13046-022-02588-8. 36627684

Echeverria GV, Cai S, Tu Y, Shao J, Powell E, Redwood AB, Jiang Y, McCoy A, Rinkenbaugh AL, Lau R, Trevarton AJ, Fu C, Gould R, Ravenberg EE, Huo L, Candelaria R, Santiago L, Adrada BE, Lane DL, Rauch GM, Yang WT, White JB, Chang JT, Moulder SL, Symmans WF, Hilsenbeck SG, Piwnica-Worms H. (2023). Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer.   NPJ breast cancer, 9, (1), 2. doi: 10.1038/s41523-022-00502-1. 36627285

Watanabe N, Mo F, Zheng R, Ma R, Bray VC, van Leeuwen DG, Sritabal-Ramirez J, Hu H, Wang S, Mehta B, Srinivasan M, Scherer LD, Zhang H, Thakkar SG, Hill LC, Heslop HE, Cheng C, Brenner MK, Mamonkin M. (2023). Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies.   Molecular therapy : the journal of the American Society of Gene Therapy, 31, (1), 24-34. doi: 10.1016/j.ymthe.2022.09.003. 36086817

Janakiraman H, Becker SA, Bradshaw A, Rubinstein MP, Camp ER. (2022). Critical evaluation of an autologous peripheral blood mononuclear cell-based humanized cancer model.   PloS one, 17, (9), e0273076. doi: 10.1371/journal.pone.0273076. 36095023

Kalra R, Chen CH, Wang J, Salam AB, Dobrolecki LE, Lewis A, Sallas C, Yates CC, Gutierrez C, Karanam B, Anurag M, Lim B, Ellis MJ, Kavuri SM. (2022). Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer.   Cancer research, 82, (16), 2928-2939. doi: 10.1158/0008-5472.CAN-21-3106. 35736563

Ravindran A, Krieger KL, Kaushik AK, Hovington H, Mehdi S, Piyarathna DWB, Putluri V, Basil P, Rasaily U, Gu F, Dang T, Choi JM, Sonavane R, Jung SY, Wang L, Mehra R, Weigel NL, Putluri N, Rowley DR, Palapattu GS, Guillemette C, Lacombe L, Lévesque É, Sreekumar A. (2022). Uridine Diphosphate Glucuronosyl Transferase 2B28 (UGT2B28) Promotes Tumor Progression and Is Elevated in African American Prostate Cancer Patients.   Cells, 11, (15), . doi: 10.3390/cells11152329. 35954173

Souto EP, Dobrolecki LE, Villanueva H, Sikora AG, Lewis MT. (2022). In Vivo Modeling of Human Breast Cancer Using Cell Line and Patient-Derived Xenografts.   Journal of mammary gland biology and neoplasia, 27, (2), 211-230. doi: 10.1007/s10911-022-09520-y. 35697909

Pal P, Millner A, Semina SE, Huggins RJ, Running L, Aga DS, Tonetti DA, Schiff R, Greene GL, Atilla-Gokcumen GE, Frasor J. (2022). Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells.   Cancers, 14, (10), . doi: 10.3390/cancers14102380. 35625985

Tian Z, Yu C, Zhang W, Wu KL, Wang C, Gupta R, Xu Z, Wu L, Chen Y, Zhang XH, Xiao H. (2022). Bone-Specific Enhancement of Antibody Therapy for Breast Cancer Metastasis to Bone.   ACS central science, 8, (3), 312-321. doi: 10.1021/acscentsci.1c01024. 35355817

Bhat R, Thangavel H, Abdulkareem NM, Vasaikar S, De Angelis C, Bae L, Cataldo ML, Nanda S, Fu X, Zhang B, Schiff R, Trivedi MV. (2022). NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer.   Scientific reports, 12, (1), 1972. doi: 10.1038/s41598-022-05949-7. 35121782

Guillen KP, Fujita M, Butterfield AJ, Scherer SD, Bailey MH, Chu Z, DeRose YS, Zhao L, Cortes-Sanchez E, Yang CH, Toner J, Wang G, Qiao Y, Huang X, Greenland JA, Vahrenkamp JM, Lum DH, Factor RE, Nelson EW, Matsen CB, Poretta JM, Rosenthal R, Beck AC, Buys SS, Vaklavas C, Ward JH, Jensen RL, Jones KB, Li Z, Oesterreich S, Dobrolecki LE, Pathi SS, Woo XY, Berrett KC, Wadsworth ME, Chuang JH, Lewis MT, Marth GT, Gertz J, Varley KE, Welm BE, Welm AL. (2022). A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology.   Nature cancer, 3, (2), 232-250. doi: 10.1038/s43018-022-00337-6. 35221336

Chen X, Clement M, Hicks MJ, Sarkar P, Gaber MW, Man TK. (2023). LOX upregulates FAK phosphorylation to promote metastasis in osteosarcoma.   Genes & diseases, 10, (1), 254-266. doi: 10.1016/j.gendis.2021.12.016. 37013056

Wang W, Han D, Cai Q, Shen T, Dong B, Lewis MT, Wang R, Meng Y, Zhou W, Yi P, Creighton CJ, Moore DD, Yang F. (2022). MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade.   Nature communications, 13, (1), 245. doi: 10.1038/s41467-021-27921-1. 35017531

Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA 2nd, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, Dipersio JF, NCI PDXNet Consortium, Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding L. (2022). Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment.   Nature communications, 13, (1), 294. doi: 10.1038/s41467-021-27678-7. 34996889

Dobrolecki LE, Lewis MT. (2022). Surgical Procedure for Implantation of Human Tumor Tissue into the Epithelium-Free Mammary Fat Pad of Immunocompromised Mice to Generate Patient-Derived Xenografts (PDX).   Methods in molecular biology (Clifton, N.J.), 2471, (), 195-207. doi: 10.1007/978-1-0716-2193-6_10. 35175598

Huang D, Chowdhury S, Wang H, Savage SR, Ivey RG, Kennedy JJ, Whiteaker JR, Lin C, Hou X, Oberg AL, Larson MC, Eskandari N, Delisi DA, Gentile S, Huntoon CJ, Voytovich UJ, Shire ZJ, Yu Q, Gygi SP, Hoofnagle AN, Herbert ZT, Lorentzen TD, Calinawan A, Karnitz LM, Weroha SJ, Kaufmann SH, Zhang B, Wang P, Birrer MJ, Paulovich AG. (2021). Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.   Cell reports. Medicine, 2, (12), 100471. doi: 10.1016/j.xcrm.2021.100471. 35028612

Kaochar S, Rusin A, Foley C, Rajapakshe K, Robertson M, Skapura D, Mason C, Berman De Ruiz K, Tyryshkin AM, Deng J, Shin JN, Fiskus W, Dong J, Huang S, Navone NM, Davis CM, Ehli EA, Coarfa C, Mitsiades N. (2021). Inhibition of GATA2 in prostate cancer by a clinically available small molecule.   Endocrine-related cancer, 29, (1), 15-31. doi: 10.1530/ERC-21-0085. 34636746

Wang Z, Hulsurkar M, Zhuo L, Xu J, Yang H, Naderinezhad S, Wang L, Zhang G, Ai N, Li L, Chang JT, Zhang S, Fazli L, Creighton CJ, Bai F, Ittmann MM, Gleave ME, Li W. (2021). CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation.   Neoplasia (New York, N.Y.), 23, (11), 1147-1165. doi: 10.1016/j.neo.2021.09.005. 34706306

Rogers JH, Gupta R, Reyes JM, Gundry MC, Medrano G, Guzman A, Aguilar R, Conneely SE, Song T, Johnson C, Barnes S, Cristobal CDD, Kurtz K, Brunetti L, Goodell MA, Rau RE. (2021). Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities.   Blood advances, 5, (19), 3876-3890. doi: 10.1182/bloodadvances.2020002408. 34492683

Ting MA, Reuther J, Chandramohan R, Voicu H, Gandhi I, Liu M, Cortes-Santiago N, Foster JH, Hicks J, Nuchtern J, Scollon S, Plon SE, Chintagumpala M, Rainusso N, Roy A, Parsons DW. (2021). Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood.   The Journal of pathology, 255, (1), 52-61. doi: 10.1002/path.5736. 34086347

Mo Y, Wang Y, Zhang S, Xiong F, Yan Q, Jiang X, Deng X, Wang Y, Fan C, Tang L, Zhang S, Gong Z, Wang F, Liao Q, Guo C, Li Y, Li X, Li G, Zeng Z, Xiong W. (2021). Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO2.   Molecular cancer, 20, (1), 112. doi: 10.1186/s12943-021-01409-4. 34465340

Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA 2nd, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, Dipersio JF, NCI PDXNet Consortium, Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding L. (2021). Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.   Nature communications, 12, (1), 5086. doi: 10.1038/s41467-021-25177-3. 34429404

Le DT, Huynh TR, Burt B, Van Buren G, Abeynaike SA, Zalfa C, Nikzad R, Kheradmand F, Tyner JJ, Paust S. (2021). Natural killer cells and cytotoxic T lymphocytes are required to clear solid tumor in a patient-derived xenograft.   JCI insight, 6, (13), . doi: 10.1172/jci.insight.140116. 34081628

Veeraraghavan J, Gutierrez C, Sethunath V, Mehravaran S, Giuliano M, Shea MJ, Mitchell T, Wang T, Nanda S, Pereira R, Davis R, Goutsouliak K, Qin L, De Angelis C, Diala I, Lalani AS, Nagi C, Hilsenbeck SG, Rimawi MF, Osborne CK, Schiff R. (2021). Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models.   NPJ breast cancer, 7, (1), 63. doi: 10.1038/s41523-021-00274-0. 34045483

Konduri V, Joseph SK, Byrd TT, Nawas Z, Vazquez-Perez J, Hofferek CJ, Halpert MM, Liu D, Liang Z, Baig Y, Salsman VS, Oyewole-Said D, Tsimelzon A, Burns BA, Chen C, Levitt JM, Yao Q, Ahmed NM, Hegde M, Decker WK. (2021). A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic ductal adenocarcinoma.   Science translational medicine, 13, (592), . doi: 10.1126/scitranslmed.abc3196. 33952672

Wang X, Veeraraghavan J, Liu CC, Cao X, Qin L, Kim JA, Tan Y, Loo SK, Hu Y, Lin L, Lee S, Shea MJ, Mitchell T, Li S, Ellis MJ, Hilsenbeck SG, Schiff R, Wang XS. (2021). Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer.   Clinical cancer research : an official journal of the American Association for Cancer Research, 27, (9), 2648-2662. doi: 10.1158/1078-0432.CCR-20-2961. 33542078

Roarty K, Echeverria GV. (2021). Laboratory Models for Investigating Breast Cancer Therapy Resistance and Metastasis.   Frontiers in oncology, 11, (), 645698. doi: 10.3389/fonc.2021.645698. 33777805

Shen T, Wang W, Zhou W, Coleman I, Cai Q, Dong B, Ittmann MM, Creighton CJ, Bian Y, Meng Y, Rowley DR, Nelson PS, Moore DD, Yang F. (2021). MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.   The Journal of clinical investigation, 131, (4), . pii: 135465. doi: 10.1172/JCI135465. 33586682

Qasim SL, Sierra L, Shuck R, Kurenbekova L, Patel TD, Rajapakshe K, Wulff J, Nakahata K, Kim HR, Landesman Y, Unger TJ, Coarfa C, Yustein JT. (2021). p21-activated kinases as viable therapeutic targets for the treatment of high-risk Ewing sarcoma.   Oncogene, 40, (6), 1176-1190. doi: 10.1038/s41388-020-01600-9. 33414491

Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH, PDXNET Consortium, EurOPDX Consortium. (2021). Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.   Nature genetics, 53, (1), 86-99. doi: 10.1038/s41588-020-00750-6. 33414553

Dustin D, Gu G, Beyer AR, Herzog SK, Edwards DG, Lin H, Gonzalez TL, Grimm SL, Coarfa C, Chan DW, Kim BJ, De La O JP, Ellis MJ, Liu D, Li S, Welm AL, Fuqua SAW. (2021). RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.   British journal of cancer, 124, (1), 191-206. doi: 10.1038/s41416-020-01174-z. 33257837

Guo Z, Primeau T, Luo J, Zhang C, Sun H, Hoog J, Gao F, Huang S, Edwards DP, Davies SR, Aft R, Ding L, Ellis MJ, Li S, Ma CX. (2020). Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models.   Cancers, 12, (12), . doi: 10.3390/cancers12123857. 33371187

Shoghi KI, Badea CT, Blocker SJ, Chenevert TL, Laforest R, Lewis MT, Luker GD, Manning HC, Marcus DS, Mowery YM, Pickup S, Richmond A, Ross BD, Vilgelm AE, Yankeelov TE, Zhou R. (2020). Co-Clinical Imaging Resource Program (CIRP): Bridging the Translational Divide to Advance Precision Medicine.   Tomography (Ann Arbor, Mich.), 6, (3), 273-287. doi: 10.18383/j.tom.2020.00023. 32879897

Rath JA, Bajwa G, Carreres B, Hoyer E, Gruber I, Martínez-Paniagua MA, Yu YR, Nouraee N, Sadeghi F, Wu M, Wang T, Hebeisen M, Rufer N, Varadarajan N, Ho PC, Brenner MK, Gfeller D, Arber C. (2020). Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8αβ-engineered human CD4(+) T cells.   Science advances, 6, (27), eaaz7809. doi: 10.1126/sciadv.aaz7809. 32923584

Zhu N, Zhang J, Du Y, Qin X, Miao R, Nan J, Chen X, Sun J, Zhao R, Zhang X, Shi L, Li X, Lin Y, Wei W, Mao A, Zhang Z, Stark GR, Wang Y, Yang J. (2020). Loss of ZIP facilitates JAK2-STAT3 activation in tamoxifen-resistant breast cancer.   Proceedings of the National Academy of Sciences of the United States of America, 117, (26), 15047-15054. doi: 10.1073/pnas.1910278117. 32532922

Bi M, Zhang Z, Jiang YZ, Xue P, Wang H, Lai Z, Fu X, De Angelis C, Gong Y, Gao Z, Ruan J, Jin VX, Marangoni E, Montaudon E, Glass CK, Li W, Huang TH, Shao ZM, Schiff R, Chen L, Liu Z. (2020). Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance.   Nature cell biology, 22, (6), 701-715. doi: 10.1038/s41556-020-0514-z. 32424275

Lv X, Dobrolecki LE, Ding Y, Rosen JM, Lewis MT, Chen X. (2020). Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer.   Journal of visualized experiments : JoVE, , (159), . doi: 10.3791/61173. 32478757

Biswal NC, Fu X, Jagtap JM, Shea MJ, Kumar V, Lords T, Roy R, Schiff R, Joshi A. (2020). In vivo longitudinal imaging of RNA interference-induced endocrine therapy resistance in breast cancer.   Journal of biophotonics, 13, (1), e201900180. doi: 10.1002/jbio.201900180. 31595691

Thangavel H, De Angelis C, Vasaikar S, Bhat R, Jolly MK, Nagi C, Creighton CJ, Chen F, Dobrolecki LE, George JT, Kumar T, Abdulkareem NM, Mao S, Nardone A, Rimawi M, Osborne CK, Lewis MT, Levine H, Zhang B, Schiff R, Giuliano M, Trivedi MV. (2019). A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer.   Journal of clinical medicine, 8, (11), . doi: 10.3390/jcm8111772. 31652963

Gómez-Miragaya J, Morán S, Calleja-Cervantes ME, Collado-Sole A, Paré L, Gómez A, Serra V, Dobrolecki LE, Lewis MT, Diaz-Lagares A, Eroles P, Prat A, Esteller M, González-Suárez E. (2019). The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.   Molecular cancer research : MCR, 17, (10), 2063-2076. doi: 10.1158/1541-7786.MCR-19-0040. 31320385

Gómez-Miragaya J, Díaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B, Wulf GM, Collado-Sole A, Trinidad EM, Muñoz P, Paré L, Prat A, Bruna A, Caldas C, Arribas J, Soler-Monso MT, Petit A, Balmaña J, Cruz C, Serra V, Pujana MA, Lewis MT, Puente XS, González-Suárez E. (2019). Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity.   Cancer research, 79, (16), 4258-4270. doi: 10.1158/0008-5472.CAN-18-3835. 31213465

Gunaratne PH, Pan Y, Rao AK, Lin C, Hernandez-Herrera A, Liang K, Rait AS, Venkatanarayan A, Benham AL, Rubab F, Kim SS, Rajapakshe K, Chan CK, Mangala LS, Lopez-Berestein G, Sood AK, Rowat AC, Coarfa C, Pirollo KF, Flores ER, Chang EH. (2019). Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.   Cancer, 125, (14), 2409-2422. doi: 10.1002/cncr.32053. 31012964

Ramirez AB, Bhat R, Sahay D, De Angelis C, Thangavel H, Hedayatpour S, Dobrolecki LE, Nardone A, Giuliano M, Nagi C, Rimawi M, Osborne CK, Lewis MT, Stilwell JL, Kaldjian EP, Schiff R, Trivedi MV. (2019). Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.   BMC cancer, 19, (1), 220. doi: 10.1186/s12885-019-5382-1. 30871481

Nardone A, Weir H, Delpuech O, Brown H, De Angelis C, Cataldo ML, Fu X, Shea MJ, Mitchell T, Veeraraghavan J, Nagi C, Pilling M, Rimawi MF, Trivedi M, Hilsenbeck SG, Chamness GC, Jeselsohn R, Osborne CK, Schiff R. (2019). The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.   British journal of cancer, 120, (3), 331-339. doi: 10.1038/s41416-018-0354-9. 30555156

Montanari M, Carbone MR, Coppola L, Giuliano M, Arpino G, Lauria R, Nardone A, Leccia F, Trivedi MV, Garbi C, Bianco R, Avvedimento EV, De Placido S, Veneziani BM. (2019). Epigenetic Silencing of THY1 Tracks the Acquisition of the Notch1-EGFR Signaling in a Xenograft Model of CD44(+)/CD24(low)/CD90(+) Myoepithelial Cells.   Molecular cancer research : MCR, 17, (2), 628-641. doi: 10.1158/1541-7786.MCR-17-0324. 30242055

Kim J, Piao HL, Kim BJ, Yao F, Han Z, Wang Y, Xiao Z, Siverly AN, Lawhon SE, Ton BN, Lee H, Zhou Z, Gan B, Nakagawa S, Ellis MJ, Liang H, Hung MC, You MJ, Sun Y, Ma L. (2018). Long noncoding RNA MALAT1 suppresses breast cancer metastasis.   Nature genetics, 50, (12), 1705-1715. doi: 10.1038/s41588-018-0252-3. 30349115

Zheng ZY, Li J, Li F, Zhu Y, Cui K, Wong ST, Chang EC, Liao YH. (2018). Induction of N-Ras degradation by flunarizine-mediated autophagy.   Scientific reports, 8, (1), 16932. doi: 10.1038/s41598-018-35237-2. 30446677

Saltzman AB, Leng M, Bhatt B, Singh P, Chan DW, Dobrolecki L, Chandrasekaran H, Choi JM, Jain A, Jung SY, Lewis MT, Ellis MJ, Malovannaya A. (2018). gpGrouper: A Peptide Grouping Algorithm for Gene-Centric Inference and Quantitation of Bottom-Up Proteomics Data.   Molecular & cellular proteomics : MCP, 17, (11), 2270-2283. doi: 10.1074/mcp.TIR118.000850. 30093420

Anurag M, Punturi N, Hoog J, Bainbridge MN, Ellis MJ, Haricharan S. (2018). Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers.   Clinical cancer research : an official journal of the American Association for Cancer Research, 24, (19), 4887-4899. doi: 10.1158/1078-0432.CCR-17-3702. 29793947

Risom T, Langer EM, Chapman MP, Rantala J, Fields AJ, Boniface C, Alvarez MJ, Kendsersky ND, Pelz CR, Johnson-Camacho K, Dobrolecki LE, Chin K, Aswani AJ, Wang NJ, Califano A, Lewis MT, Tomlin CJ, Spellman PT, Adey A, Gray JW, Sears RC. (2018). Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer.   Nature communications, 9, (1), 3815. doi: 10.1038/s41467-018-05729-w. 30232459

Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Peres RMR, Punturi N, Schmidt C, Bartram A, Jou E, Devarakonda V, Holloway KR, Lai WV, Hampton O, Rogers A, Tobias E, Parikh PA, Davies SR, Li S, Ma CX, Suman VJ, Hunt KK, Watson MA, Hoadley KA, Thompson EA, Chen X, Kavuri SM, Creighton CJ, Maher CA, Perou CM, Haricharan S, Ellis MJ. (2018). Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.   Cell reports, 24, (6), 1434-1444.e7. doi: 10.1016/j.celrep.2018.07.009. 30089255

Wang X, Tan Y, Cao X, Kim JA, Chen T, Hu Y, Wexler M, Wang X. (2018). Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity.   Oncotarget, 9, (53), 30115-30127. doi: 10.18632/oncotarget.25728. 30046392

Mundt F, Rajput S, Li S, Ruggles KV, Mooradian AD, Mertins P, Gillette MA, Krug K, Guo Z, Hoog J, Erdmann-Gilmore P, Primeau T, Huang S, Edwards DP, Wang X, Wang X, Kawaler E, Mani DR, Clauser KR, Gao F, Luo J, Davies SR, Johnson GL, Huang KL, Yoon CJ, Ding L, Fenyö D, Ellis MJ, Townsend RR, Held JM, Carr SA, Ma CX. (2018). Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.   Cancer research, 78, (10), 2732-2746. doi: 10.1158/0008-5472.CAN-17-1990. 29472518

Yue Z, Yuan Z, Zeng L, Wang Y, Lai L, Li J, Sun P, Xue X, Qi J, Yang Z, Zheng Y, Fang Y, Li D, Siwko S, Li Y, Luo J, Liu M. (2018). LGR4 modulates breast cancer initiation, metastasis, and cancer stem cells.   FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 32, (5), 2422-2437. doi: 10.1096/fj.201700897R. 29269400

Zhao N, Cao J, Xu L, Tang Q, Dobrolecki LE, Lv X, Talukdar M, Lu Y, Wang X, Hu DZ, Shi Q, Xiang Y, Wang Y, Liu X, Bu W, Jiang Y, Li M, Gong Y, Sun Z, Ying H, Yuan B, Lin X, Feng XH, Hartig SM, Li F, Shen H, Chen Y, Han L, Zeng Q, Patterson JB, Kaipparettu BA, Putluri N, Sicheri F, Rosen JM, Lewis MT, Chen X. (2018). Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer.   The Journal of clinical investigation, 128, (4), 1283-1299. doi: 10.1172/JCI95873. 29480818

Byrd TT, Fousek K, Pignata A, Szot C, Samaha H, Seaman S, Dobrolecki L, Salsman VS, Oo HZ, Bielamowicz K, Landi D, Rainusso N, Hicks J, Powell S, Baker ML, Wels WS, Koch J, Sorensen PH, Deneen B, Ellis MJ, Lewis MT, Hegde M, Fletcher BS, St Croix B, Ahmed N. (2018). TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.   Cancer research, 78, (2), 489-500. doi: 10.1158/0008-5472.CAN-16-1911. 29183891

Guo S, Zhang C, Bratton M, Mottamal M, Liu J, Ma P, Zheng S, Zhong Q, Yang L, Wiese TE, Wu Y, Ellis MJ, Matossian M, Burow ME, Miele L, Houtman R, Wang G. (2018). ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models.   Oncotarget, 9, (6), 6924-6937. doi: 10.18632/oncotarget.24023. 29467940

Pillai SG, Li S, Siddappa CM, Ellis MJ, Watson MA, Aft R. (2018). Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.   Breast cancer research : BCR, 20, (1), 2. doi: 10.1186/s13058-017-0927-1. 29291741

Nishimura CD, Brenner DA, Mukherjee M, Hirsch RA, Ott L, Wu MF, Liu H, Dakhova O, Orange JS, Brenner MK, Lin CY, Arber C. (2017). c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals.   Blood, 130, (25), 2739-2749. doi: 10.1182/blood-2017-02-769463. 29079582

Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, Caldas C, Christie AL, Clark DA, Dowst H, Dry JR, Doroshow JH, Duchamp O, Evrard YA, Ferretti S, Frese KK, Goodwin NC, Greenawalt D, Haendel MA, Hermans E, Houghton PJ, Jonkers J, Kemper K, Khor TO, Lewis MT, Lloyd KCK, Mason J, Medico E, Neuhauser SB, Olson JM, Peeper DS, Rueda OM, Seong JK, Trusolino L, Vinolo E, Wechsler-Reya RJ, Weinstock DM, Welm A, Weroha SJ, Amant F, Pfister SM, Kool M, Parkinson H, Butte AJ, Bult CJ. (2017). PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.   Cancer research, 77, (21), e62-e66. doi: 10.1158/0008-5472.CAN-17-0582. 29092942

Wang X, Mooradian AD, Erdmann-Gilmore P, Zhang Q, Viner R, Davies SR, Huang KL, Bomgarden R, Van Tine BA, Shao J, Ding L, Li S, Ellis MJ, Rogers JC, Townsend RR, Fenyö D, Held JM. (2017). Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner.   Science signaling, 10, (491), . doi: 10.1126/scisignal.aam8065. 28790197

Guven A, Villares GJ, Hilsenbeck SG, Lewis A, Landua JD, Dobrolecki LE, Wilson LJ, Lewis MT. (2017). Carbon nanotube capsules enhance the in vivo efficacy of cisplatin.   Acta biomaterialia, 58, (), 466-478. doi: 10.1016/j.actbio.2017.04.035. 28465075

Zhang J, Song F, Zhao X, Jiang H, Wu X, Wang B, Zhou M, Tian M, Shi B, Wang H, Jia Y, Wang H, Pan X, Li Z. (2017). EGFR modulates monounsaturated fatty acid synthesis through phosphorylation of SCD1 in lung cancer.   Molecular cancer, 16, (1), 127. doi: 10.1186/s12943-017-0704-x. 28724430

Neelakantan D, Zhou H, Oliphant MUJ, Zhang X, Simon LM, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, Lewis MT, Ford HL. (2017). EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells.   Nature communications, 8, (), 15773. doi: 10.1038/ncomms15773. 28604738

Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, Jiang H, Hu J, Xu F, Zhao Y, Liu L, Fernandez-Salas E, Xu J, Dou Y, Wen B, Sun D, Meagher J, Stuckey J, Hayes DF, Li S, Ellis MJ, Wang S. (2017). Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer.   Cancer research, 77, (9), 2476-2487. doi: 10.1158/0008-5472.CAN-16-2622. 28209615

Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T, Sheng K, Dobrolecki LE, Zhang X, Putluri N, Phung TL, Mani SA, Stossi F, Sreekumar A, Mancini MA, Decker WK, Zong C, Lewis MT, Zhang XH. (2017). Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming.   Nature, 544, (7649), 250-254. doi: 10.1038/nature21724. 28371798

Huang KL, Li S, Mertins P, Cao S, Gunawardena HP, Ruggles KV, Mani DR, Clauser KR, Tanioka M, Usary J, Kavuri SM, Xie L, Yoon C, Qiao JW, Wrobel J, Wyczalkowski MA, Erdmann-Gilmore P, Snider JE, Hoog J, Singh P, Niu B, Guo Z, Sun SQ, Sanati S, Kawaler E, Wang X, Scott A, Ye K, McLellan MD, Wendl MC, Malovannaya A, Held JM, Gillette MA, Fenyö D, Kinsinger CR, Mesri M, Rodriguez H, Davies SR, Perou CM, Ma C, Reid Townsend R, Chen X, Carr SA, Ellis MJ, Ding L. (2017). Proteogenomic integration reveals therapeutic targets in breast cancer xenografts.   Nature communications, 8, (), 14864. doi: 10.1038/ncomms14864. 28348404